[go: up one dir, main page]

BRPI0817535B8 - método in vitro eficiente para obter células apresentadoras de antígenos ativadas (apcs), especialmente células dendríticas (dcs), úteis na preparação de vacinas para o tratamento do câncer - Google Patents

método in vitro eficiente para obter células apresentadoras de antígenos ativadas (apcs), especialmente células dendríticas (dcs), úteis na preparação de vacinas para o tratamento do câncer

Info

Publication number
BRPI0817535B8
BRPI0817535B8 BRPI0817535A BRPI0817535A BRPI0817535B8 BR PI0817535 B8 BRPI0817535 B8 BR PI0817535B8 BR PI0817535 A BRPI0817535 A BR PI0817535A BR PI0817535 A BRPI0817535 A BR PI0817535A BR PI0817535 B8 BRPI0817535 B8 BR PI0817535B8
Authority
BR
Brazil
Prior art keywords
cancer
useful
cells
apcs
dcs
Prior art date
Application number
BRPI0817535A
Other languages
English (en)
Inventor
Felipe Escobar Alvarez Alejandro
Javier Pereda Ramos Cristian
Andrés Salazar Onfray Flavio
Natalia Lopez Nitsche Mercedes
Elvira Aguilera Insunza Raquel
Original Assignee
Oncobiomed
Oncobiomed Advanced Cell Tech S A
Univ Chile
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncobiomed, Oncobiomed Advanced Cell Tech S A, Univ Chile filed Critical Oncobiomed
Publication of BRPI0817535A2 publication Critical patent/BRPI0817535A2/pt
Publication of BRPI0817535B1 publication Critical patent/BRPI0817535B1/pt
Publication of BRPI0817535B8 publication Critical patent/BRPI0817535B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4271—Melanoma antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4274—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; Prostatic acid phosphatase [PAP]; Prostate-specific G-protein-coupled receptor [PSGR]
    • A61K40/4275—Prostate specific antigen [PSA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/428—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/70—Undefined extracts
    • C12N2500/80—Undefined extracts from animals
    • C12N2500/84—Undefined extracts from animals from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/02—Compounds of the arachidonic acid pathway, e.g. prostaglandins, leukotrienes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/05—Adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/05—Adjuvants
    • C12N2501/056—Immunostimulating oligonucleotides, e.g. CpG
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/07—Heat shock proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/24—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/25—Tumour necrosing factors [TNF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Mycology (AREA)

Abstract

método in vitro, em duas etapas, para obter células apresentadas de antígenos ativadas (apcs), especialmente as células dendríticas (dcs),úteis na preparação de vacinas para o tratamento do câncer ou outras enfermidades relacionadas ao sistema imunológico. a presente invenção refere-se a um processo ex vivo, rápido eficiente para obter células apresentadoras de antígenos ativadas que são úteis para terapias contra o câncer e doenças relacionadas ao sistema imunológico. ao mesmo tempo, ela se refere a uma composição celular que contribui para estimular as células apresentadoras de antígenos ativadas a induzir uma resposta imune especifica contra os tumores em pacientes com câncer ou outras patologias que envolvam respostas imunes.
BRPI0817535A 2007-09-28 2008-09-26 método in vitro eficiente para obter células apresentadoras de antígenos ativadas (apcs), especialmente células dendríticas (dcs), úteis na preparação de vacinas para o tratamento do câncer BRPI0817535B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CL2825/2007 2007-09-28
CL200702825A CL2007002825A1 (es) 2007-09-28 2007-09-28 Metodo para generar vacunas que estimulen el sistema inmune que comprende inducir celulas mononucleares de sangre periferica a que se diferencien a apc, para luego, separar dichas apc y mezclarlas con adyuvantes; extracto de celulas tumorales; y comp
PCT/EP2008/062909 WO2009040413A2 (en) 2007-09-28 2008-09-26 An ex vivo, fast and efficient process to obtain activated antigen-presenting cells that are useful for therapies against cancer and immune system-related diseases

Publications (3)

Publication Number Publication Date
BRPI0817535A2 BRPI0817535A2 (pt) 2015-03-31
BRPI0817535B1 BRPI0817535B1 (pt) 2020-10-27
BRPI0817535B8 true BRPI0817535B8 (pt) 2021-05-25

Family

ID=40261519

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0817535A BRPI0817535B8 (pt) 2007-09-28 2008-09-26 método in vitro eficiente para obter células apresentadoras de antígenos ativadas (apcs), especialmente células dendríticas (dcs), úteis na preparação de vacinas para o tratamento do câncer

Country Status (11)

Country Link
US (2) US20100303868A1 (pt)
EP (1) EP2222331A2 (pt)
AR (1) AR068984A1 (pt)
AU (1) AU2008303453B2 (pt)
BR (1) BRPI0817535B8 (pt)
CA (1) CA2700942A1 (pt)
CL (1) CL2007002825A1 (pt)
IL (1) IL204821A (pt)
MX (1) MX2010003415A (pt)
NZ (1) NZ584606A (pt)
WO (1) WO2009040413A2 (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010119307A1 (en) 2009-04-14 2010-10-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for stimulating antigen-specific t cell responses using accelerated co-cultured dendritic cells
EP3424522A1 (en) * 2010-03-15 2019-01-09 The Trustees Of The University Of Pennsylvania System and method of preparing and storing activated mature dendritic cells
WO2012017033A1 (en) 2010-08-04 2012-02-09 Ieo-Istituto Europeo Di Oncologia S.R.L. Method of antigen loading for immunotherapy
US20160017293A1 (en) * 2012-08-15 2016-01-21 Neostem Oncology, Llc Individualized high purity hepatocellular carcinoma stem cells, methods and use of the same
CN105050617A (zh) * 2012-12-28 2015-11-11 阿姆弗拉公司 免疫原性裂解物的制备方法、获得的裂解物、负载有该裂解物的树突状细胞以及含有该裂解物或树突状细胞的药物组合物
EP3167898A1 (en) 2015-11-11 2017-05-17 IEO - Istituto Europeo di Oncologia Srl Method for obtaining tumor peptides and uses thereof
AU2020231936A1 (en) * 2019-03-06 2021-10-14 Universidad De Chile Immunogenic formulations for treating cancer
IN201921052318A (pt) * 2019-12-17 2019-12-20 Senthilkumar NATESAN
CN112111453A (zh) * 2020-09-11 2020-12-22 河北佑仁生物科技有限公司 一种免疫细胞培养体系优化方法及活性检测方法
CN114246942A (zh) * 2020-09-24 2022-03-29 刘慧宁 肿瘤复合抗原、树突状细胞多价疫苗及其应用
CN113444687A (zh) * 2021-05-31 2021-09-28 浙江圣希澳医学科技有限公司 穿膜肽介导肿瘤抗原多肽致敏转染cd40l的dc疫苗及dc-ctl方法
CN114288396A (zh) * 2021-12-21 2022-04-08 皖南医学院第一附属医院（皖南医学院弋矶山医院） 一种肿瘤个体化dc疫苗、制备方法及应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6121044A (en) * 1995-07-12 2000-09-19 Dendreon Corporation Potent antigen presenting cell composition
US20020155108A1 (en) * 1998-05-04 2002-10-24 Biocrystal, Ltd. Method for ex vivo loading of antigen presenting cells with antigen, and a vaccine comprising the loaded cells
JP2000143534A (ja) 1998-11-13 2000-05-23 Asahi Chem Ind Co Ltd 樹状細胞ワクチン及びその製造方法
EP1054351A3 (en) 1999-05-20 2003-06-18 TeraRecon, Inc., A Delaware Corporation Method and apparatus for classifying intensity values of volume data using a reconfigurable look-up table
EP1254953A4 (en) * 1999-12-28 2004-06-02 Toyoshima Kumao Maturity-triggering agent for immature dendritic cells
IL140796A0 (en) 2001-01-08 2002-02-10 Hadasit Med Res Service An autologous anti-cancer vaccine
EP1530628B1 (en) * 2002-08-16 2010-09-29 Glycotope GmbH Process for the production of temperature-induced tumor cell lysates for use as immunogenic compounds
US20060239962A1 (en) * 2002-12-04 2006-10-26 Banchereau Jacques F Rapid one-step generation of antigen loaded dendritic cell vaccine from precursors
JP5623004B2 (ja) * 2004-10-25 2014-11-12 ベイラー リサーチ インスティテュートＢａｙｌｏｒ Ｒｅｓｅａｒｃｈ Ｉｎｓｔｉｔｕｔｅ 熱ショックをかけたメラノーマ細胞体が装填された樹状細胞
WO2006073921A2 (en) * 2004-12-30 2006-07-13 The Rockefeller University Compositions and methods for enhanced dendritic cell maturation and function

Also Published As

Publication number Publication date
CL2007002825A1 (es) 2008-05-30
IL204821A (en) 2015-04-30
EP2222331A2 (en) 2010-09-01
CA2700942A1 (en) 2009-04-02
BRPI0817535B1 (pt) 2020-10-27
AR068984A1 (es) 2009-12-23
WO2009040413A2 (en) 2009-04-02
US20100303868A1 (en) 2010-12-02
BRPI0817535A2 (pt) 2015-03-31
MX2010003415A (es) 2010-07-05
US20140072596A1 (en) 2014-03-13
IL204821A0 (en) 2010-11-30
WO2009040413A3 (en) 2009-11-19
AU2008303453B2 (en) 2013-06-06
NZ584606A (en) 2012-08-31
US9694059B2 (en) 2017-07-04
AU2008303453A1 (en) 2009-04-02

Similar Documents

Publication Publication Date Title
BRPI0817535B8 (pt) método in vitro eficiente para obter células apresentadoras de antígenos ativadas (apcs), especialmente células dendríticas (dcs), úteis na preparação de vacinas para o tratamento do câncer
MX336839B (es) Formacion de complejos de acidos nucleicos con componentes cationicos entrelazados por disulfuro para transfeccion e inmunoestimulacion.
CY1121789T1 (el) Νεες ανοσοενισχυτικες συνθεσεις
WO2015149944A3 (en) Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant
CY1116090T1 (el) Μεθοδος για σχηματισμο γελης φιμπροϊνης μεταξης χρησιμοποιωντας κατεργασια υπερηχων
BR112013031084A2 (pt) meios e métodos para imunoterapia celular ativa de câncer usando células tumorais mortas por alta pressão hidrostática e células dendríticas
ATE522600T1 (de) Anti-tumor impfstoff aus normalen chemisch modifizierten cd4+ zellen
WO2008040362A3 (en) Generation of a cancer-specific immune response toward muc1 and cancer specific muc1 antibodies
MY157661A (en) Bendamustine pharmaceutical compositions
BR112012026953A8 (pt) Composto, uso de um composto, composição farmacêutica, e processo para preparar uma composição farmacêutica
CR9748A (es) Derivados de xantina como agonistas selectivos de hm74a
NO20083722L (no) Immunogen sammensetning
WO2008064299A3 (en) Methods of reducing porcine circovirus-associated disease outbreaks
BR112014008700A2 (pt) composições úteis no tratamento de nefropatia e processos para preparação das mesmas
CL2021001563A1 (es) Péptidos y combinación de péptidos novedosos para su uso en inmunoterapia contra diversos tumores (divisional de la solicitud no. 201702407)
BRPI0314373B8 (pt) produto imunogênico estável para a indução de anticorpos contra uma ou várias proteínas antigênicas em um indivíduo, composições farmacêutica, imunogênica e de vacina e processo de preparação de um produto imunogênico
ECSP088636A (es) Antígenos de ácido des-n-acetil-siálico, anticuerpos para los mismos, y métodos de uso en la terapia de cáncer
BRPI0607551A2 (pt) vacinas de combinação de helicobacter e circovìrus porcino e métodos de uso
BR112012014624A2 (pt) suspensão homogênea de compostos de imunopotenciação e usos dos destes
WO2006071983A3 (en) Use of compositions comprising various tumor-associated antigens as anti-cancer vaccines
BR112013029417A2 (pt) composições de vacina de matriz proteica incluindo policátions
BR112012015449A2 (pt) suspensão de monoidrato de calcipotriol, monoidrato de calcipotriol, processo para preparar nanocristais de monoidrato de calcipotriol, e, composição farmacêutica
AR041086A1 (es) Vacuna
BRPI0918226A2 (pt) composição imunogênica, método para produzir uma composição imunogênica, método para elicitar uma resposta imune contra neisseria, uso da composição imunogênica, e, vacina
BR112014017819A8 (pt) Método de produzir células cancerígenas imunogênicas isoladas, células cancerígenas imunogênicas isoladas, composição imunogênica e vacina autóloga de câncer

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: UNIVERSIDAD DE CHILE (CL)

B25A Requested transfer of rights approved

Owner name: UNIVERSIDAD DE CHILE (CL)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 27/10/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 26/09/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF